172 related articles for article (PubMed ID: 769971)
1. Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.
Johnson RO; Metter G; Wilson W; Hill G; Krementz E
Cancer Treat Rep; 1976 Feb; 60(2):183-7. PubMed ID: 769971
[TBL] [Abstract][Full Text] [Related]
2. DTIC (NSC-45388) studies in the southwest oncology group.
Costanzi JJ
Cancer Treat Rep; 1976 Feb; 60(2):189-92. PubMed ID: 769972
[TBL] [Abstract][Full Text] [Related]
3. Eastern Cooperative Oncology Group studies with DTIC (NSC-45388).
Carbone PP; Costello W
Cancer Treat Rep; 1976 Feb; 60(2):193-8. PubMed ID: 769973
[TBL] [Abstract][Full Text] [Related]
4. DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065).
Carter RD; Krementz ET; Hill GJ; Metter GE; Fletcher WS; Golomb FM; Grage TB; Minton JP; Sparks FC
Cancer Treat Rep; 1976 May; 60(5):601-9. PubMed ID: 991149
[TBL] [Abstract][Full Text] [Related]
5. DTIC (NSC-45388) in malignant melanoma: a perspective.
Comis RL
Cancer Treat Rep; 1976 Feb; 60(2):165-76. PubMed ID: 769969
[No Abstract] [Full Text] [Related]
6. Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma.
Bellett RE; Mastrangelo MJ; Laucius JF; Bodurtha AJ
Cancer Treat Rep; 1976 May; 60(5):595-600. PubMed ID: 791478
[TBL] [Abstract][Full Text] [Related]
7. Combination cytotoxic chemotherapy for metastatic cutaneous malignant melanoma with DTIC, BCNU, and vincristine.
Carmo-Pereira J; Oliveira Costa F; Pimentel P
Cancer Treat Rep; 1976 Sep; 60(9):1381-3. PubMed ID: 1016972
[No Abstract] [Full Text] [Related]
8. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
[TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy with DTIC (NSC-45388) in advanced malignant melanoma, soft tissue sarcomas, and Hodgkin's disease.
Beretta G; Bonadonna G; Bajetta E; Tancini G; De Lena M; Azzarelli A; Veronesi U
Cancer Treat Rep; 1976 Feb; 60(2):205-11. PubMed ID: 769975
[TBL] [Abstract][Full Text] [Related]
10. Clinical studies with DTIC (NSC-45388) in various malignancies.
Slavik M
Cancer Treat Rep; 1976 Feb; 60(2):213-4. PubMed ID: 769976
[No Abstract] [Full Text] [Related]
11. Combination chemotherapy for disseminated malignant melanoma with DTIC, vincristine, and methyl-CCNU.
Einhorn LH; Furnas B
Cancer Treat Rep; 1977 Aug; 61(5):881-3. PubMed ID: 329981
[TBL] [Abstract][Full Text] [Related]
12. [Polychemotherapy with 5-(3,3 dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC; NSC-45388), 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC-409962) and vincristine (NSC-67574) in the metastatic phase of melanoma].
Beretta G; Bajetta E; Bonadonna G; Tancini G; Orefice S; Veronesi U
Tumori; 1973; 59(3):239-48. PubMed ID: 4729646
[No Abstract] [Full Text] [Related]
13. Phase I--II study of intermittent bolus administration of DTIC and actinomycin D in metastatic malignant melanoma.
Samson MK; Baker LH; Talley RW; Fraile RJ; McDonald B
Cancer Treat Rep; 1978 Aug; 62(8):1223-5. PubMed ID: 356980
[TBL] [Abstract][Full Text] [Related]
14. [DTIC in malignant melanoma: a perspective (author's transl)].
Kokoschka EM
Wien Klin Wochenschr; 1978 Dec; 90(24):870-4. PubMed ID: 369152
[TBL] [Abstract][Full Text] [Related]
15. [Chemotherapy of malignant melanoma. Results of a controlled clinical trial comparing vincristine + dacarbazin (DTIC) with and without duborimycin (author's transl)].
Chauvergne J; Clavel B; Klein T; Pommatau E
Bull Cancer; 1978; 65(2):107-9. PubMed ID: 359067
[TBL] [Abstract][Full Text] [Related]
16. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas.
Gottlieb JA; Benjamin RS; Baker LH; O'Bryan RM; Sinkovics JG; Hoogstraten B; Quagliana JM; Rivkin SE; Bodey GP; Rodriguez V; Blumenschein GR; Saiki JH; Coltman C; Burgess MA; Sullivan P; Thigpen T; Bottomley R; Balcerzak S; Moon TE
Cancer Treat Rep; 1976 Feb; 60(2):199-203. PubMed ID: 769974
[TBL] [Abstract][Full Text] [Related]
17. Influence of therapy on the antioxidant status in patients with melanoma.
Gadjeva V; Dimov A; Georgieva N
J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
[TBL] [Abstract][Full Text] [Related]
18. Use of combination chemotherapy with CCNU, bleomycin, and vincristine in the treatment of metastatic melanoma in patients resistant to DTIC therapy.
Everall JD; Dowd PM
Cancer Treat Rep; 1979 Jan; 63(1):151-5. PubMed ID: 84710
[No Abstract] [Full Text] [Related]
19. Phase 1-11 study of DTIC and cyclocytidine in disseminated malignant melanoma.
Samson MK; Baker LH; Izbicki RM; Ratanatharathorn V
Cancer Treat Rep; 1976 Sep; 60(9):1369-71. PubMed ID: 65223
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of metastatic malignant melanoma (author's transl)].
Kühböck J; Pehamberger H; Mach K; Diem E; Kokoschka EM; Pötzi P
Wien Klin Wochenschr; 1978 Dec; 90(24):856-8. PubMed ID: 84441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
